Harmony Biosciences Holdings, Inc.

For the period ended Sep 30, 2025. Filed Nov 4, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 4, 2025

HRMY$33.55-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets (Unaudited)

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS


· September 30, · December 31,
· 2025 · 2024
ASSETS · ·
CURRENT ASSETS: · ·
Cash and cash equivalents	$646,999	$453,001
Investments, short-term	25,582	14,185
Trade receivables, net	100,651	83,033
Inventory, net	6,882	7,198
Prepaid expenses	23,308	13,714
Other current assets	35,378	8,121
Total current assets	838,800	579,252
NONCURRENT ASSETS:
Property and equipment, net	1,440	1,257
Investments, long-term	105,831	108,874
Intangible assets, net	95,380	113,263
Deferred tax asset	157,075	190,398
Other noncurrent assets	9,692	6,156
Total noncurrent assets	369,418	419,948
TOTAL ASSETS	$1,208,218	$999,200
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables	$26,341	$13,744
Accrued compensation	14,935	18,776
Accrued expenses	161,302	120,640
Current portion of long-term debt	20,000	16,250
Other current liabilities	825	5,672
Total current liabilities	223,403	175,082
NONCURRENT LIABILITIES:
Long-term debt, net	148,506	163,016
Other noncurrent liabilities	1,186	1,947
Total noncurrent liabilities	149,692	164,963
TOTAL LIABILITIES	373,095	340,045
COMMITMENTS AND CONTINGENCIES (Note 13)
STOCKHOLDERS’ EQUITY:
Common stock—$0.00001 par value; 500,000,000 shares authorized at September 30, 2025 and December 31, 2024, respectively; 57,596,358 and 57,144,887 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	1	1
Additional paid in capital	696,348	656,872
Accumulated other comprehensive income	357	66
Retained earnings	138,417	2,216
TOTAL STOCKHOLDERS’ EQUITY	835,123	659,155
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$1,208,218	$999,200

UNAUDITED CONDENSED CONSOLIDATED

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.